Donepezil News and Research

RSS

Donepezil is a drug that is used to treat Alzheimer disease and is being studied in the treatment of side effects caused by radiation therapy to the brain. It is a type of cholinesterase inhibitor.

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

World's largest autism science and advocacy organization awards 16 new research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 16 new research grants totaling $5,223,743 over the next three years.

9 Apr 2010

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.

3 Mar 2010

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.

18 Feb 2010

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease.

12 Jan 2010

FDA approves generic donepezil hydrochloride orally disintegrating tablets

The U.S. Food and Drug Administration approved the first generic versions of Aricept (donepezil hydrochloride) orally disintegrating tablets on Dec. 11. Donepezil hydrochloride is indicated for the treatment of dementia related to Alzheimer's disease.

5 Jan 2010

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc.

16 Dec 2009

Eisai's NDA for Aricept tablets for treatment of Alzheimer's disease accepted for review

Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD).

25 Nov 2009

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD).

4 Nov 2009

Bradycardia more likely in patients taking cholinesterase inhibitors

People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

3 Oct 2009

Depression may increase risk of Alzheimer's disease in people with memory problems

People with memory problems who are depressed are more likely to develop Alzheimer's disease compared to people who are not depressed, according to a study published in the June 16, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology. However, the research also shows that the popular Alzheimer's drug donepezil may delay the progression to Alzheimer's disease for depressed people with mild cognitive impairment (MCI) or memory problems.

15 Jun 2009

Scientists predict new uses for existing drugs from their side effects

Researchers from the European Molecular Biology Laboratory (EMBL) discovered a new way to make use of drugs' unwanted side effects. They developed a computational method that compares how similar the side effects of different drugs are and predicts how likely the drugs act on the same target molecule. The study, published in Science this week, hints at new uses of marketed drugs.

10 Jul 2008

Dual treatment of incontinence and dementia associated with functional decline

Older nursing home residents who took medications for dementia and incontinence at the same time had a 50 percent faster decline in function than those who were being treated only for dementia, according to a study from researchers at Wake Forest University School of Medicine and colleagues.

1 May 2008

Dual treatment of incontinence and dementia associated with functional decline

30 Apr 2008

Memantine and Alzheimer's

In a study published this month in the Journal of Alzheimer's Disease, researchers from the University of Aberdeen report that the drug memantine, used for the treatment of Alzheimer's disease and praised as "the first and only representative of a new class of Alzheimer drugs" works in fact similar to other existing compounds, and is beneficial only in a narrow concentration range.

14 Jan 2008

Review of Memantine for Alzheimer's

11 Jan 2008

Cholinesterase inhibitors do not seem to delay Alzheimer disease

Researchers have examined the evidence in favour of giving people considered to be close to developing dementia the drugs that are most commonly used to treat the condition itself.

27 Nov 2007

Donepezil no better than placebo to treat behavioural symptoms of Alzheimer's

New research has found that donepezil (known commercially as Aricept©) is no more effective than a placebo at tackling the agitation which often accompanies Alzheimer's disease.

4 Oct 2007

donepezil improves symptoms of severe Alzheimer's

A drug initially used to treat mild to moderate Alzheimer's disease improved the memory and global function of people with severe Alzheimer's disease and was safe and effective, according to a study published in the July 31, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.

1 Aug 2007

Furore over who gets Alzheimer's drug in the UK

A furore has erupted in Britain over a decision by the National Institute for Clinical Excellence (NICE), not to recommend the use of an Alzheimer's drug for newly diagnosed patients.

20 Nov 2006

Donepezil News and Research

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

World's largest autism science and advocacy organization awards 16 new research grants

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

FDA approves generic donepezil hydrochloride orally disintegrating tablets

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Eisai's NDA for Aricept tablets for treatment of Alzheimer's disease accepted for review

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Bradycardia more likely in patients taking cholinesterase inhibitors

Depression may increase risk of Alzheimer's disease in people with memory problems

Scientists predict new uses for existing drugs from their side effects

Dual treatment of incontinence and dementia associated with functional decline

Dual treatment of incontinence and dementia associated with functional decline

Memantine and Alzheimer's

Review of Memantine for Alzheimer's

Cholinesterase inhibitors do not seem to delay Alzheimer disease

Donepezil no better than placebo to treat behavioural symptoms of Alzheimer's

donepezil improves symptoms of severe Alzheimer's

Furore over who gets Alzheimer's drug in the UK

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News